Delivery Order SPE2DB20D3103-SPE2DB25FP5V2
- Not listed
- The Defense Logistics Agency awarded a $3,689.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Entresto 24 mg-26 mg tablets (60-count supply) on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-competitive delivery order was placed against AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled at...
- The Defense Logistics Agency awarded a $68,784.07 delivery order to AmerisourceBergen Drug Corp for the supply of Entresto 49 mg-51 mg tablets (180-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a direct fulfillment under the company's broader pharmaceutical supply arrangements. The place of performance is AmerisourceBergen's corporate office location...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,026.86 to AmerisourceBergen Drug Corp for 60 tablets of Entresto 24 mg-26 mg on July 30, 2025, with completion scheduled for July 31, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,346.88 to AmerisourceBergen Drug Corp for the supply of Entresto 97 mg-103 mg tablets (180-count) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a non-competitive award under the company's broader indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,262.40 to AmerisourceBergen Drug Corp for the supply of Entresto 49 mg-51 mg tablets (180-count), with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Entresto 24 mg-26 mg tablets (60-count) at a ceiling value of $2,846.54. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and represents a non-competitive, non-set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a $7,996.94 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Entresto 97 mg-103 mg tablets (180-count). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 29, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under a larger contract vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Entresto 49 mg-51 mg tablets (180-count supply) with a ceiling value of $51,539.65. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a competitively awarded contract with no set-aside designation. The work will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Entresto 24 mg-26 mg tablets (60-count packaging) with a ceiling value of $5,642.09. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion by July 29, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $2,440.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Entresto 49 mg-51 mg tablets (180-count units). This contract, which is not set-aside and was competitively awarded, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP5V2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,003.10 to AmerisourceBergen Drug Corp for the supply of Entresto 49 mg-51 mg tablets (180-count units). This is a firm fixed-price delivery order with no set-aside designation, awarded on July 21, 2025, with an ultimate completion date of July 22, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal healthcare vendor that supplies comprehensive medical products including brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through competitive contract awards with the DLA. Entresto is a combination cardiovascular medication commonly used in heart failure treatment, reflecting the company's role in supplying essential medications to support military and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 7/21/25 |